EyeBiotech Ltd. clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 3 with minor changes only.

1. Minor

   MALBEC · EYE201/MK-8748 · Macular Degeneration (MK-8748-002)

   Trial sites expanded: 124 → 132 locations

   And 1 more change in the last 30 days

   EyeBiotech Ltd.·Phase 2/3· NCT07440225· Registry history of NCT07440225 on ClinicalTrials.gov (opens the registry)

   Updated Oct 2, 2026

2. Minor

   BAROLO · Remigromig (EYE103) Compared With Ranibizumab (0.5 mg)…BAROLO · Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) · DME

   Interventions modified

   EyeBiotech Ltd.·Phase 2/3· NCT06957080· Registry history of NCT06957080 on ClinicalTrials.gov (opens the registry)

   Updated Oct 15, 2026

3. Minor

   BRUNELLO · Remigromig (EYE103) Compared With Ranibizumab (0.5…BRUNELLO · Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) · DME

   Interventions modified

   And 1 more change in the last 30 days

   EyeBiotech Ltd.·Phase 2/3· NCT06571045· Registry history of NCT06571045 on ClinicalTrials.gov (opens the registry)

   Updated Oct 14, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.